The global scale-up of antiretroviral (ARV) therapy (ART) has led to dramatic reductions in
HIV-1 mortality and incidence. However, HIV drug resistance (HIVDR) poses a potential …

The 1980s saw the devastation of the newly emerging and deadly disease of acquired
immunodeficiency syndrome (AIDS). The identification of the retrovirus, now known as …

Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …

Background Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug
regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and …

Background The widespread use of the integrase strand transfer inhibitor (INSTI)
dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate …

ABSTRACT Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of
HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …

Background Among some patients with human immunodeficiency virus type 1 (HIV-1)
infection who have undergone multiple antiretroviral therapies and have limited options for …

Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretroviral drugs to be
approved for treatment and act by inhibiting the essential HIV protein integrase from …